Elanco Animal Health (ELAN) Long-Term Investments (2017 - 2018)
Elanco Animal Health (ELAN) reported Long-Term Investments of $15.3 million for Q4 2018, up 24.39% on a YoY basis from $12.3 million in Q4 2017, and up 2.68% sequentially from $14.9 million in Q3 2018.
Elanco Animal Health (ELAN) Long-Term Investments (2017 - 2018) Analysis & Trends
Elanco Animal Health (ELAN) has 2 years of Long-Term Investments data on file, last reported at $15.3 million in Q4 2018.
- For the quarter ending Q4 2018, Long-Term Investments rose 24.39% year-over-year to $15.3 million; the trailing twelve-month figure through Dec 2018 stood at $15.3 million (up 24.39% YoY), and the FY2018 full-year result was $15.3 million, up 24.39% from the prior year.
- Long-Term Investments advanced to $15.3 million in Q4 2018, from $14.9 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $15.3 million in Q4 2018 to a low of $12.3 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 15.30 Mn |
| Sep 30, 2018 | 14.90 Mn |
| Dec 31, 2017 | 12.30 Mn |